SAB Biotherapeutics, based in Sioux Falls, has received a grant of over one point four million dollars from the National Institute of Health to advance its treatment for influenza.
It is a research project in conjunction with the USD Sanford School of Medicine.

Eddie Sullivan, President and CEO of SAB, says the cooperation from USD Sanford is critical…..

SAB uses special cows injected with flu vaccine. They then take antibodies produced by the cows, and further purify them.
Sullivan says those antibodies could treat someone already infected with the flu…..

Sullivan says the grant could help them greatly expand their research in antibody use…..

It is a two year research grant that runs through 2018.